In colorectal cancer it has been suggested that the TIMP-1 protein could be a possible new biomarker predicting the effect of treatment with irinotecan [42], and the potential of TIMP-1 as a predictive biomarker in glioblastomas needs to be further investigated in regard to sensitivity to irinotecan treatment. The gene discussed is TIMP1; the disease is glioblastoma.